Michael Mejia
@mikemejiamd
Followers
831
Following
4K
Media
74
Statuses
3K
Chair, Department of Radiation Oncology University of Santo Tomas Hospital. Head and Neck Unit BCI Tweets are my own.
Manila City, National Capital
Joined May 2010
Still of the conviction that most #nasopharyngealcarcinoma is best treated by upfront CCRT so would’ve been an outlier vote here. ACT with cape or GP for high risk.
Interesting poll from #NasopharyngealCarcinoma. Meeting in Guangzhou among Chinese Experte. What should be the SOC for high-risk NPC trial? @imrtlee @Qle_stanford @sueyom @mikemejiamd @lachiemcd @Larvol @oncodaily . In case translation is needed, option 1 is IC+CRT and option 2
0
0
4
Questions hopefully answered.
📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studies (n=8,119).⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb! .➡️link
0
0
0
RT @Icro_Meattini: Regional nodal irradiation in negative nodal status and after primary systemic therapy - amazing teaching lecture by Phi….
0
42
0
We’re honored to have our work featured by ASTRO! What started as a determined effort in resource-limited settings has grown into something we’re truly proud of. We hope to bridge important knowledge gaps in the understanding and management of #NPC.@WarrenBacorro @DrMLChua.
New in #practicalRO: International Consensus Guidelines on the Delineation of Radiation Therapy Target Volumes for Nasopharyngeal Carcinoma After Induction Chemotherapy Using a 2-Round Modified Delphi Survey #radonc
0
0
3
First of 2 consensus statements coming out for #NPC. This one is an effort undertaken with most of the participants from #LMIC settings. Excellent inclusivity effort from @WarrenBacorro and team.
0
3
4
Future directions in #hncsm is #SBRT. Not new in NPC as it was part of our reRT cohort (, but it may be time to increase breadth and depth.
ascopubs.org
PURPOSEThe objectives of this study were to report the oncologic outcomes and the treatment-related toxicities after reirradiation (re-RT) for recurrent nasopharyngeal carcinoma (rNPC) at our...
Beauty of #AcademicMedicine is so that people from around the world can brainstorm on care of patients. Happy that we can share our experience with #SRS #SBRT for #HeadNeckCancer #NPC patients, in this case a young lady from Romania! @mikemejiamd . Makes my day and perhaps the
1
1
2
Expanding the role of SABR in #headandneckcancer is always both challenging and exciting. Kudos to GORTEC.
Hot of the press @IJROBP: Role of SABR in oligometastatic head and neck cancer: a GORTEC randomized trial . Full text here:
0
2
9
RT @EChrisDee: Grateful to Dr @LuisaJacomina and our entire team Dr @MikeMejiaMD, Dr Cherry Estilo, Dr Gelo Militante, Dr Ian Fernando, and….
0
4
0
#hncsm #npc .It’s time to have that conversation of reducing toxicity for select patients. Volume reduction may be one avenue to achieve this the more we know about the behavior of the disease .@WarrenBacorro @luisajacomina @EChrisDee.
This may not be "practice-changing" per se but kudos to the investigators for running this trial. I have known Prof Tang for many years now and she is a solid clinician who has prob treated more #NPC than most of us (even experts) around the world! . Look out for more.
0
3
11
RT @EChrisDee: The @USTFMSofficial and #Philippine #Dental Association #oral #oncology seminar series 🇵🇭. Dr @MikeMejiaMD's introduction to….
0
3
0
Fantastic summary of MDT trials and directions in OMBC! Key question to our #bcsm #radonc #sbrt folks: DOES an oligometastatic state exist in breast cancer?.@luisajacomina @IBCradiation @SFShaitelmanMD @CJTsaiMDPhD @drdavidpalma.
🧵 SBRT in Oligometastatic Breast Cancer: What does the evidence show? A summary of key studies and their impact on survival. Let’s dive in! 👇. 1/ What is Oligometastatic Breast Cancer (OMBC)?.OMBC is an intermediate state between localized and widespread metastatic disease,.
1
0
4
Brilliant explanations below 👇.
My brilliant med student asked me to explain correlation, causation, confounding &collider bias. I used the following ex… so sharing here in case anyone finds it helpful! . PS -I have learned much from @dnunan79 @Catalogofbias - a great resource for EBM. hopefully he approves😅
0
0
0
RT @DBelardoMD: My brilliant med student asked me to explain correlation, causation, confounding &collider bias. I used the following ex… s….
0
1K
0
👏👏👏.
In today’s @QuadShotNews and now on @IJROBP as pre-proof‼️. Excited to share our study on palliative RT for breast cancer @MDAndersonNews . 💖RT is effective in palliating symptoms from LABC.💕More RT isn’t always better (or necessary?).💘QOL is 🔑.
0
0
1
Kudos to @NRGonc HN team led by @Qle_stanford and @sueyom for publishing HN004. Need to identify better treatment options for curable cisplatin ineligible #hncsm patients.
Final results of NRG HN004 coming out in Lancet Oncology, press release to follow, RT/cetux results look relatively strong for cisplatin ineligible HNSCC
0
1
8
Need a more robust discussion to redefine patient selection for MDT as this is now a moving target. @CJTsaiMDPhD @_ShankarSiva @DrMLChua @VedangMurthy @drkevin_chua_lm.
"Oligo"-no more! 🇨🇦ARREST phase I out now @IJROBP - @sueyom .➡️SABR to median=16 "poly"metastases in patients who had already exhausted multiple lines of systemic therapy.➡️4x dose levels (up to 6Gyx5). ➡️No safety signals, QoL maintained. Congrats! 👏👏
0
0
5
Excellent work by my colleague @WarrenBacorro from @UST1611official and the GEC ESTRO on HN #radonc #brachytherapy.
Just published online! GEC-ESTRO recommendations for #headandneckcancer #brachytherapy (interventional #radiotherapy): 2nd update with focus on HDR and PDR. 👉 Read the article:
0
0
1
Cisplatin still king in fit patients.Important to properly select patients who are not cisplatin candidates.But does avelumab really improve outcomes? (p=0.059).Important work nonetheless at #ESMO2024 in #hncsm .Glad to see #radonc papers in #medonc meetings.
Congrats to my friend @YG_TAO & GORTEC for this huge trial of IO in LA HNSCC. Avelumab-cetuximab inferior to cisplatin CRT in fit patients but superior to cetuximab-RT for PFS in cisplatin ineligible population. #ESMO2024
0
2
5
Easy to understand talk with excellent synthesis. Kudos @VedangMurthy from @TataMemorial . @luisajacomina .@EChrisDee .@MichelleEalaMD .@DrMLChua .@drkevin_chua_lm.
#ESTROAsia24 . @VedangMurthy giving an elegant overview as always on role of pelvic node irradiation in #ProstateCancer . Amazing how many trials @TataMemorial run for #GUCancers . @piet_ost @TylerSbrt @AmarUKishan @mikemejiamd @scserendipity1 @aleberlin2 @alison_tree
0
2
12